Biolinerx (BLRX) Posts Q1 Loss of 1c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Aegis Keeps BioLineRx (BLRX) at 'Buy'; Plenty of Catalysts Happening Over Next 12 Months
May 21, 2014 9:26 AM EDTAegis Capital maintained BioLineRx, Ltd. (Nasdaq: BLRX) at Buy with a $7 price target following Q1 results. After markets closed Tuesday, BioLineRx reported Q1 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11).
Analyst Ram Selvaraju said, The firm ended the quarter with $37.5mm in cash, following a recent financing round that raised $24.1mm in net proceeds from the sale of roughly 9.7mm American... More



